REPLY Extends Its Presence in Banks and Insurance in Germany With the Acquisition of FINCON
REPLY [EXM, STAR: REY] announces today that has signed an agreement to acquire 100% of FINCON Unternehmensberatung GmbH (www.fincon.eu) - a German consulting company leader in digital transformation projects for the banking and the insurance industry.
FINCON, headquartered in Hamburg, is a pure consulting company specialized on the core processes and systems for the financial services industry such as, mobile banking, payments, core banking, internal control system and regulatory compliance, BIPRO and insurance systems. Among the customers of FINCON there are the main German banking and insurance institutions and many of the German Sparkasse.
The investment in FINCON is part of Reply's international growth strategy, particularly in Germany, where Reply is already a leading player in consulting, system integration and digital services.
The managing directors of FINCON with the role of "Partner Reply" will focus on further developing and expanding the activities of FINCON within the Reply Group in Germany.
"FINCON - said Mario Rizzante, President of Reply - mixes a great expertise on banking and insurance processes with a constant attention to technological innovation. With FINCON our goal is to expand Reply footprint into the German banking and insurance sector with a focus on digital transformation projects an area where all the main industry players are concentrating the majority of their investments.”
Frank Dünnleder, CEO of FINCON commented: "We are very excited to be joining Reply’s network of companies as the leading consulting company for the financial services industry in Germany. The strong interest in people, culture and customer focus that characterize Reply fits perfectly with our corporate culture. As part of the Reply network, we benefit from the innovative power and creativity of the entire group, which enables us to support our customers even better and more comprehensive with cutting edge solutions and services.”
The completion of the transaction is subject to fulfilment of certain conditions, such as the clearance by the German Federal Cartel Office. Completion is expected to occur towards the end of June 2022.
REPLY
Reply [EXM, STAR: REY, ISIN: IT0005282865] is specialized in the design and implementation of solutions based on new communication channels and digital media. Reply is a network of highly focused companies supporting key European industrial groups operating in the telecom and media, industry and services, banking, insurance and public administration sectors in the definition and development of business models enabled for the new paradigms of AI, cloud computing, digital media and the Internet of Things. Reply services include: Consulting, System Integration and Digital Services. www.reply.com
FINCON
With around 450 employees, FINCON Unternehmensberatung GmbH is the consulting and solutions company specializing in banks, the savings bank financial group and the insurance industry. In the banking segment, FINCON advises major banks, the cooperative financial group and selected foreign and specialist banks on specialist, technical, process-related and project methodological issues. www.fincon.eu
This press release is a translation, the Italian version will prevail.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220524005727/en/
Contact information
REPLY
Media Contacts
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594
Joerg Naruhn
j.naruhn@reply.com
Tel. +49524150090
Investor Relation Contacts
Riccardo Lodigiani
r.lodigiani@reply.com
Tel. +390117711594
Michael Lueckenkoetter
m.lueckenkoetter@reply.com
Tel. +49524150091017
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aptiv and Vecna Robotics to Develop Next Generation Autonomous Mobile Robots18.12.2025 14:00:00 CET | Press Release
Aptiv PLC (NYSE: APTV), a global industrial technology leader, and Vecna Robotics, a pioneer in AI-driven autonomous material handling solutions, today announced a strategic collaboration to co-develop next-generation Autonomous Mobile Robot (AMR) solutions designed to deliver cost-efficient automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218958100/en/ Aptiv’s advanced perception portfolio and machine learning technologies will be integrated into Vecna Robotics’ platform. This partnership combines Aptiv’s industry-leading portfolio, with Vecna Robotics’ advanced autonomy and orchestration platform to provide safer, more efficient, and scalable material handling systems. “Automation is transforming the way goods move through warehouses and factories, with devices that sense, think and act in real time,” said Javed Khan, Executive Vice President, Intelligent Systems, Aptiv. “Our collaboration with Vecna Robotics
Syremis Therapeutics Launches with $165M to Develop Best-in-Class Medicines for Mental Health Conditions18.12.2025 14:00:00 CET | Press Release
Syremis Therapeutics, a clinical-stage biopharmaceutical company developing novel medicines to make a profound impact on the treatment of mental health, today announced its launch with a $165 million financing. The Series A, co-led by Dexcel Pharma and Third Rock Ventures, with participation from Bain Capital Life Sciences, GV (Google Ventures), QVT, and Pictet will support the advancement of Syremis’ pipeline through clinical proof of concept. Schizophrenia and other psychotic disorders remain among the most debilitating and underserved conditions worldwide, with more than 20 million people affected and facing considerable disability, elevated relapse rates, and reduced life expectancy. Despite decades of need, current treatments often fall short in both efficacy and tolerability. Syremis’ lead program, ST-905, is a dual M1/M4 muscarinic agonist under development for schizophrenia and other neuropsychiatric conditions and is currently in Phase 1. The molecule’s differentiated potency
Cinemo at CES 2026: Hyper-Personalized Experiences in the Car and Beyond18.12.2025 13:55:00 CET | Press Release
Cinemo, a global leader and highly innovative one-stop-shop provider for fully integrated digital media products is presenting its newest innovations in exclusive live demos at CES 2026 in Las Vegas, from January 6-9. Cinemo will present a range of in-car experiences that bring intelligence, hyper-personalization, and entertainment to every moment - elevating every ride into a unique experience for drivers and passengers. From collaborative trip planning to effortless onboarding, every feature is crafted to enable fascinating experiences with the right content at the right time for the right audience - for the perfect ride. Passengers can enjoy personalized media recommendations, immersive gaming, and a consistent, intuitive experience across every seat, screen, and journey. This will mark Cinemo’s first time presenting these demo showcases live of breakthrough solutions that redefine the future of in-vehicle intelligence. Cinemo is bringing agentic AI into the vehicle and is extending
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currently conducting a global, multi-center Phase 1 clinical trial (NCT06427941) to explore the safety and anti-tumor activity of BGB-B2033, both alone and in combination with PD-1 inhibitor TEVIMBRA® (tisle
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press Release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom